The Trendlines Group Ltd. (TRNLY) Income Statement Analysis

See more : Waa Solar Limited (WAA.BO) Income Statement Analysis – Financial Results

Complete financial analysis of The Trendlines Group Ltd. (TRNLY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of The Trendlines Group Ltd., a leading company in the Asset Management industry within the Financial Services sector.

You may be interested

The Trendlines Group Ltd. (TRNLY)

Industry: Asset Management

Sector: Financial Services

Website: https://www.trendlines.com

About The Trendlines Group Ltd.

The Trendlines Group Ltd. is an innovation commercialization company and a private equity and venture capital firm specializing in incubation, seed, start-up, early venture and late venture investments. The firm seeks to invest in food, clean technology, agritechnology, lifesciences with a focus on medical devices, biotechnology, and pharmaceuticals, security, medical, and information technology companies. It considers investments in Israel and Singapore. The firm offers business incubation, partner and channel development, market strategies, business plans, research and development and commercialization activities, business development, finance and funding strategies, administrative services and marketing communications services to entrepreneurs. The firm seeks to invest a minimum of $0.06 million in its portfolio companies. The firm prefers to exit its investments through merger and acquisition transactions, listing on public stock exchanges, or other dispositions of holdings. It leverages its own capital with government funding to mitigate risk in creating and developing new businesses. It is involved in all aspects of its portfolio companies from technology development to business building. The Trendlines Group Ltd. was founded in 1993 and is based in M.P. Misgav, Israel with additional offices in Tel Aviv, Israel; Beijing, China; and Singapore, Singapore.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	-20.99M	3.58M	2.30M	3.72M	5.50M	6.24M	5.21M	7.21M	4.56M	5.95M	29.52M	13.77M
Cost of Revenue	5.65M	8.10M	8.51M	2.11M	938.45K	4.80M	5.67M	5.32M	4.83M	5.75M	5.53M	4.63M
Gross Profit	-26.64M	-4.52M	-6.21M	1.61M	4.56M	1.44M	-463.00K	1.89M	-264.00K	205.00K	23.99M	9.14M
Gross Profit Ratio	126.91%	-126.44%	-269.71%	43.34%	82.94%	23.06%	-8.89%	26.26%	-5.79%	3.44%	81.27%	66.36%
Research & Development	1.69M	916.00K	345.00K	1.09M	1.11M	1.06M	195.00K	224.00K	110.00K	514.00K	1.45M	1.12M
General & Administrative	3.77M	3.28M	2.68M	7.48M	7.06M	6.40M	3.07M	3.39M	1.86M	1.76M	394.00K	184.00K
Selling & Marketing	241.00K	270.00K	328.00K	214.00K	269.00K	404.00K	354.00K	390.00K	243.00K	320.00K	315.00K	139.00K
SG&A	4.01M	3.55M	3.01M	214.00K	269.00K	404.00K	3.42M	3.78M	2.11M	2.08M	709.00K	323.00K
Other Expenses	0.00	3.40M	-8.05M	18.48M	3.31M	360.00K	355.00K	432.00K	417.00K	717.00K	0.00	0.00
Operating Expenses	1.93M	7.86M	-4.70M	19.78M	4.69M	13.90M	-5.03M	12.65M	-2.20M	2.84M	680.00K	410.00K
Cost & Expenses	11.75M	15.96M	3.81M	19.78M	4.69M	13.90M	645.00K	17.97M	2.63M	8.59M	6.21M	5.04M
Interest Income	17.00K	35.00K	22.00K	3.93M	256.00K	1.25M	97.00K	123.00K	245.00K	5.00K	405.00K	117.00K
Interest Expense	20.00K	5.90M	206.00K	860.00K	1.24M	428.00K	10.00K	46.00K	549.00K	699.00K	0.00	0.00
Depreciation & Amortization	772.00K	955.69K	1.10M	1.77M	789.31K	285.11K	189.04K	162.46K	165.00K	105.00K	83.00K	75.00K
EBITDA	-33.93M	-17.83M	2.68M	-11.56M	2.16M	-5.77M	5.77M	-9.69M	2.52M	-1.81M	23.37M	9.38M
EBITDA Ratio	161.66%	-293.29%	171.79%	-288.70%	39.18%	-92.53%	110.71%	-134.54%	60.70%	-34.21%	79.15%	64.56%
Operating Income	-32.74M	-11.42M	2.85M	-12.09M	1.38M	-5.86M	5.59M	-9.86M	2.35M	-1.92M	23.29M	8.81M
Operating Income Ratio	156.00%	-319.28%	123.90%	-325.18%	25.04%	-93.99%	107.20%	-136.69%	51.58%	-32.21%	78.87%	64.02%
Total Other Income/Expenses	-2.58M	-6.20M	3.19M	227.00K	-671.00K	-65.18K	-356.39K	796.00K	-3.49M	127.00K	-376.00K	-204.00K
Income Before Tax	-35.32M	-17.32M	2.65M	-12.95M	137.00K	-6.49M	5.58M	-9.93M	-1.77M	-2.86M	22.91M	8.61M
Income Before Tax Ratio	168.30%	-484.04%	114.95%	-348.32%	2.49%	-104.01%	107.01%	-137.78%	-38.89%	-47.97%	77.60%	62.54%
Income Tax Expense	-600.79K	-2.16M	-3.36M	-9.00M	832.00K	-168.00K	1.64M	-3.36M	1.79M	1.36M	6.19M	2.64M
Net Income	-34.00M	-15.16M	6.56M	-3.95M	-695.00K	-6.12M	3.86M	-6.58M	-3.30M	-2.81M	15.96M	5.83M
Net Income Ratio	161.97%	-423.78%	285.22%	-106.30%	-12.64%	-98.16%	74.15%	-91.23%	-72.31%	-47.28%	54.04%	42.32%
EPS	-1.83	-0.02	0.01	-0.01	0.00	-0.50	0.37	-0.65	-0.45	-0.45	0.05	0.02
EPS Diluted	-1.83	-0.02	0.01	-0.01	0.00	-0.50	0.37	-0.65	-0.45	-0.45	0.05	0.02
Weighted Avg Shares Out	18.56M	840.46M	791.19M	791.19M	655.20M	12.17M	10.51M	10.17M	7.31M	6.32M	319.72M	300.45M
Weighted Avg Shares Out (Dil)	18.56M	840.46M	791.19M	791.19M	655.20M	12.17M	10.51M	10.17M	7.31M	6.32M	317.83M	287.71M

Vessi Medical Closes $16.5 Million Series A Round for Innovative Cryotherapy Bladder Cancer Treatment

February 14, 2024prnewswire.com

Investors include an undisclosed global strategic investor , ALIVE VC and Agriline MISGAV, Israel , Feb. 14, 2024 /PRNewswire/ -- Vessi Medical Ltd. ("Vessi") announced today that it has closed a Series A financing round of $16.5 million for its cryotherapy...